Baldachin: Ceiling HEPA-filtration to Prevent Nosocomial Transmission of COVID-19

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Dec 12, 2022

Keywords

ClinConnect Summary

The Baldachin trial is studying a new way to help prevent the spread of COVID-19 in hospital settings. Specifically, it looks at using a special air filtration unit, called a HEPA filter, in areas where multiple patients with COVID-19 are being treated together. This trial aims to see if this filtration system can reduce the risk of the virus spreading from one patient to another in shared spaces.

To take part in this study, individuals must be adult patients currently in the hospital with a confirmed COVID-19 infection, and their symptoms or positive test must have occurred within the last 10 days. Unfortunately, pregnant individuals or those who are unable to give consent cannot participate. If eligible, participants can expect to be in an area equipped with this new air filter while still receiving their usual hospital care, and their health will be monitored closely to evaluate the effectiveness of this intervention.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult inpatients of included open-space IMC units with lab-confirmed SARS-CoV-2 infection, symptom onset or date of test ≤10 days prior inclusion.
• Exclusion Criteria:
• • Pregnancy, unability to give consent (e.g. informed consent form not available in patient language or non-judicious)

Trial Officials